NAMPT and relapsing-remitting multiple sclerosis: Considering that disease modifying therapies exert potent immunomodulatory and anti-inflammatory effects, we hypothesized that serum visfatin levels in treated RRMS patients might not follow the classical pro-inflammatory profile but rather reflect treatment efficacy and long-term disease control.